What Are GLP-1 Medications?
GLP-1 receptor agonists are a class of injectable (and now oral) medications that mimic glucagon-like peptide-1, a hormone produced in the gut after eating. They slow digestion, reduce appetite, lower blood sugar, and — when used at higher doses — produce significant weight loss. FDA-approved GLP-1 drugs include semaglutide (Ozempic for diabetes, Wegovy for weight loss), tirzepatide (Mounjaro for diabetes, Zepbound for weight loss), dulaglutide (Trulicity), and oral semaglutide (Rybelsus).
All currently available GLP-1 medications are brand-name drugs with no U.S. generic equivalents approved as of 2026. This makes them among the most expensive medications prescribed in the United States, with retail prices ranging from $935 to $1,349 per month depending on the drug and dose. Despite high costs, demand has surged as clinical evidence has mounted showing substantial weight loss outcomes and cardiovascular benefits.
How to Pay Less for GLP-1 Medications
Manufacturer savings cards — Novo Nordisk offers a savings card for Ozempic and Wegovy; Eli Lilly offers one for Mounjaro and Zepbound. Commercially insured patients who qualify can pay as little as $0–$25/month. Coverage rules, income limits, and eligibility criteria vary. Medicare and Medicaid patients generally cannot use manufacturer copay cards.
Insurance coverage — Many commercial insurance plans now cover GLP-1 drugs for Type 2 diabetes (Ozempic, Mounjaro) but may require prior authorization or step therapy. Coverage for weight loss indications (Wegovy, Zepbound) is less consistent — some plans cover it, others explicitly exclude it. Check your plan's formulary and appeal coverage denials if applicable.
Medicare coverage — As of 2026, Medicare Part D covers Wegovy for cardiovascular risk reduction in patients who meet clinical criteria. Coverage for weight loss alone remains limited under Medicare, though policy is evolving. The $35 insulin cap under Medicare does not apply to GLP-1 drugs.
Compounded alternatives — When brand-name GLP-1 drugs are on FDA shortage lists, licensed compounding pharmacies may produce lower-cost compounded semaglutide or tirzepatide. Compounded formulations are not FDA-approved; consult your prescriber about risks and regulations.
Telehealth programs — Several telehealth platforms specialize in GLP-1 prescriptions and may bundle consultation, medication, and monitoring at a lower total cost than retail pharmacy channels for uninsured patients.
GLP-1 Medication Price Comparisons
- Ozempic (semaglutide 0.5mg–1mg) — Compare Pharmacy Prices
- Wegovy (semaglutide 2.4mg) — Compare Pharmacy Prices
- Mounjaro (tirzepatide) — Compare Pharmacy Prices
- Zepbound (tirzepatide) — Compare Pharmacy Prices
- Trulicity (dulaglutide) — Compare Pharmacy Prices
- Rybelsus (oral semaglutide) — Compare Pharmacy Prices